This
week I received a message: -
“Your Bumetanide treatment is on trial among
25 teenagers here and parents are loving it”
My
reply, brief as usual (unlike my blog posts)
“Great!”
I did
not mention that in the first phase of the trial 50% of the teenagers are going
to be on the placebo. It is Dr Ben-Ari’s
treatment.
A
clinician told me that all the parents of children, to whom she has prescribed
bumetanide, think their children are responders and is wondering how to deal with
the parental placebo effect.
I had
another clinician telling me, “I guess from your experience with the blog, most
people are not responders to Bumetanide”. Then came an analysis of the recent tiny
study in China that showed on average there was a measurable improvement on the
CARS scale (Childhood Autism Rating Scale), but the question arose was “is this
response large enough for parents to notice?”
Memantine (Namenda)
A few
years ago, Memantine was also trialled at the University Hospital where we
live, the same one that is part of the current Bumetanide study.
Memantine
was subject to a rigorous multi-center study of nearly one thousand children a
few years ago. The FDA did not like all
the off-label prescribing of Memantine for autism and asked the producer to
carry out a serious clinical trial.
The
first phase of the trial was to identify the responders, those responders then
were to be enrolled to two follow-on trials to collect additional useful
data. The trial was terminated after the
first phase was completed because in the subsequent trials the placebo produced
as good results as Memantine.
So,
we should assume memantine is no good for autism?
Or
In
spite of spending millions of dollars and liaising with the FDA on the detailed
structure of the trial, the producer did not know how to organize an autism
trial properly?
I was
just writing a part of my autism book that reviews all the drugs trialed to
date in autism and I noted that Antonio Hardan (for me, Dr NAC from Stanford)
has published a review of data from those expensive Memantine trials.
… the considerable
improvements in mean Social Responsiveness Scale scores from baseline in the
open-label trials were presumed to be clinically important.
I
think that is Hardan-speak for “I think Memantine can be a useful therapy, for
some people”. I am not totally sure and I can see why Barney Rubble might be left scratching his head.
Hardan is about to become Stanford's Dr Nexium, as he runs a clinical trial of the acid lowering drug esomeprazole (Nexium). I am not sure why he thinks this will improve autism. I think it will make some people's autism worse, because over time it will cause intestinal dysbiosis.
https://stanfordhealthcare.org/trials/a/NCT03866668.html
Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use
Hardan is about to become Stanford's Dr Nexium, as he runs a clinical trial of the acid lowering drug esomeprazole (Nexium). I am not sure why he thinks this will improve autism. I think it will make some people's autism worse, because over time it will cause intestinal dysbiosis.
https://stanfordhealthcare.org/trials/a/NCT03866668.html
Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use
Autism for Dummies?
Writing a comprehensive book about autism is
quite a task. If it is too complicated
nobody will read it, but if you do not go into the how and why of autism, you
have not contributed very much.
My elder son has suggested calling it “Autism
for Dummies”; but that was not helpful suggestion. We probably all count as Dummies, when it
comes to autism, even Dr Naviaux, who I think knows the most.
Before using pharmaceuticals to treat autism,
we used a Peter-created, ABA-inspired, home therapy program. Amongst many resources, we had two old, but
excellent books - they were published nearly 40 years ago. One was blue and one was yellow (code named
by me and therapists as the yellow and blue books), one was about increasing
good behaviors and the other was about reducing bad behaviors. I could not leave them lying around at home,
because in the tittle of these use cute looking books was in large print “SEVERE
RETARDATION”. The books are great and of
course they should have been combined into a single book.
I am not a fan of giving a nice name to
somethings that is bad.
To me, intellectual disability sounds like
not being very good at playing chess.
Accept bad news and move on.
Peter’s Book
I decided to have three sections in my book
and have a nice cookery book style cheerful cover, so nobody can be
embarrassed. I will not be citing
endless complicated research papers.
I start with all the general issues that are
relevant to understanding autism, that do not relate to complicated
science. I finish with a section on how autism
can be treated based on applying the research findings to date, what ideas I
came up with myself and other people’s ideas shared on this blog.
Sandwiched in between easy reading section 1
and practical section 3, is a more heavy-going section 2; it is a simplified
review of the biology and chemistry that is relevant to autism. These are things you need to know to make any
sense of those tens of thousands of published autism papers, that most people
do not know exist.
Section 2 is not going to be a favourite for Roger,
but I think he will like sections 1 and 3.
To really judge what to do in the therapy part (section 3),
understanding at least part of section 2 is advisable and that is why it has to
be there.
It is just like fixing your car, it does help
to know a little bit about how it works, before you start tinkering with it. Even the mechanic at the dealership does not know
everything about how it works, but hopefully he knows enough.
If the mechanic cannot fix your car, you just
sell it. You may feel a pain in your wallet, but no long-term guilt.